DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Solifenacin for overactive bladder: secondary analysis of data from VENUS based on baseline continence status.

Author(s): Toglia MR, Ostergard DR, Appell RA, Andoh M, Fakhoury A, Hussain IF.

Affiliation(s): Urogynecology Associates of Philadelphia, Outpatient Pavilion, Suite 3404, 1098 West Baltimore Pike, Media, PA 19063, USA. togliam@verizon.net

Publication date & source: 2010, Int Urogynecol J. , 21(7):847-54

INTRODUCTION AND HYPOTHESIS: VENUS evaluated the efficacy of solifenacin on urgency in patients with overactive bladder (OAB). We hypothesized that solifenacin would be comparably efficacious in continent and incontinent patients. METHODS: VENUS was a 12-week, placebo-controlled trial in patients with OAB. Treatment efficacy was assessed using bladder diaries and patient-reported outcome measures. The primary endpoint was the change in daily urgency episodes. Exploratory subgroup analyses were conducted using baseline continence status. RESULTS: Solifenacin reduced urgency episodes versus placebo in continent (-3.4 vs. -2.3) and incontinent patients (-4.2 vs. -2.9) and incontinence episodes (-2.1 vs. -1.2) in that subgroup; 58% versus 42% of incontinent patients receiving solifenacin versus placebo were continent at study end. In both cohorts, solifenacin- versus placebo-treated patients showed greater improvements in perceptions of urgency severity, symptom bother, and health-related quality of life. CONCLUSION: This post hoc analysis demonstrates the efficacy of solifenacin regardless of baseline continence status.

Page last updated: 2013-02-10

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017